West Nile virus/dengue type 4 virus chimeras that are reduced in neurovirulence and peripheral virulence without loss of immunogenicity or protective efficacy - Wikidata - wikimedia - TriplyDB

West Nile virus/dengue type 4 virus chimeras that are reduced in neurovirulence and peripheral virulence without loss of immunogenicity or protective efficacy

West Nile virus/dengue type 4 virus chimeras that are reduced in neurovirulence and peripheral virulence without loss of immunogenicity or protective efficacy

http://www.wikidata.org/entity/Q27471660

about

Chemokine receptor CCR5 promotes leukocyte trafficking to the brain and survival in West Nile virus infection Predicting Zika virus structural biology: Challenges and opportunities for intervention Flaviviral NS4b, chameleon and jack-in-the-box roles in viral replication and pathogenesis, and a molecular target for antiviral intervention Recovery of West Nile Virus Envelope Protein Domain III Chimeras with Altered Antigenicity and Mouse Virulence Chimeric Dengue 2 PDK-53/West Nile NY99 Viruses Retain the Phenotypic Attenuation Markers of the Candidate PDK-53 Vaccine Virus and Protect Mice against Lethal Challenge with West Nile Virus Envelope protein glycosylation status influences mouse neuroinvasion phenotype of genetic lineage 1 West Nile virus strains.A nonsense mutation in the gene encoding 2'-5'-oligoadenylate synthetase/L1 isoform is associated with West Nile virus susceptibility in laboratory mice A tick-borne Langat virus mutant that is temperature sensitive and host range restricted in neuroblastoma cells and lacks neuroinvasiveness for immunodeficient mice Preparation and immunogenic properties of a recombinant West Nile subunit vaccine A mouse cell-adapted NS4B mutation attenuates West Nile virus RNA synthesis Comparative Neuropathogenesis and Neurovirulence of Attenuated Flaviviruses in Nonhuman Primates Production and characterization of vaccines based on flaviviruses defective in replication Evaluation of St. Louis encephalitis virus/dengue virus type 4 antigenic chimeric viruses in mice and rhesus monkeys A recombinant West Nile virus envelope protein vaccine candidate produced in Spodoptera frugiperda expresSF+ cells Efficacy of killed virus vaccine, live attenuated chimeric virus vaccine, and passive immunization for prevention of West Nile virus encephalitis in hamster model Immunogenicity and Protective Efficacy of a Recombinant Subunit West Nile Virus Vaccine in Rhesus Monkeys Induction of endoplasmic reticulum-derived replication-competent membrane structures by West Nile virus non-structural protein 4B The chimeric Japanese encephalitis/Dengue 2 virus protects mice from challenge by both dengue virus and JEV virulent virus A recombinant influenza A virus expressing domain III of West Nile virus induces protective immune responses against influenza and West Nile virus Japanese encephalitis virus vaccine candidates generated by chimerization with dengue virus type 4 Assurance of neuroattenuation of a live vaccine against West Nile virus: a comprehensive study of neuropathogenesis after infection with chimeric WN/DEN4Δ30 vaccine in comparison to two parental viruses and a surrogate flavivirus reference vaccine.Replacement of the 3' untranslated variable region of mosquito-borne dengue virus with that of tick-borne Langat virus does not alter vector specificity.Dual miRNA targeting restricts host range and attenuates neurovirulence of flaviviruses.Structure and function of the 3' terminal six nucleotides of the west nile virus genome in viral replication.Mutational analysis of the West Nile virus NS4B protein.Microarray hybridization for assessment of the genetic stability of chimeric West Nile/dengue 4 virus Induction of antigen-specific immune responses in mice by recombinant baculovirus expressing premembrane and envelope proteins of West Nile virus.Replacement of conserved or variable sequences of the mosquito-borne dengue virus 3' UTR with homologous sequences from Modoc virus does not change infectivity for mosquitoes The Emerging Duck Flavivirus Is Not Pathogenic for Primates and Is Highly Sensitive to Mammalian Interferon Antiviral Signaling.TLR9-targeted biodegradable nanoparticles as immunization vectors protect against West Nile encephalitis.The live attenuated chimeric vaccine rWN/DEN4Δ30 is well-tolerated and immunogenic in healthy flavivirus-naïve adult volunteers.Safety and efficacy of chimeric yellow Fever-dengue virus tetravalent vaccine formulations in nonhuman primates.Vaccines and immunotherapeutics for the prevention and treatment of infections with West Nile virus.Substitution of the premembrane and envelope protein genes of Modoc virus with the homologous sequences of West Nile virus generates a chimeric virus that replicates in vertebrate but not mosquito cells A Live Attenuated Chimeric West Nile Virus Vaccine, rWN/DEN4Δ30, Is Well Tolerated and Immunogenic in Flavivirus-Naive Older Adult Volunteers.Location and role of free cysteinyl residues in the Sindbis virus E1 and E2 glycoproteins.Exchanging the yellow fever virus envelope proteins with Modoc virus prM and E proteins results in a chimeric virus that is neuroinvasive in SCID mice.US in grip of West Nile virus.

P2860

Q24646031-2056F256-96C8-47D6-A238-26B9E092FAB5 Q24700044-7108E613-8480-4BB8-9C28-BD952B98D7C9 Q26314693-82EA4599-0C4A-4904-8A48-F013AADE71FA Q27469118-95420A58-D277-4663-8735-CFCAA4F5A689 Q27469831-E3A39284-FDEA-4BC8-9BE6-C05237AFE39D Q27469847-C715A2D0-A771-4BE4-87A4-AFB4A95400CC Q27471916-A50433A1-AF83-4203-9D0E-79A173F55E78 Q27472824-EE14DE6A-F67B-4778-ACAE-268F395C2AF5 Q27478202-7EB1FD76-149B-4E6D-894D-7D883E559C4C Q27481037-87118421-E2E8-43DE-AB24-00AFA78631CC Q27486117-A11125CA-5465-4BA5-BF78-EA9BB2207835 Q27486374-DA6F986D-5478-482F-A249-F222ACD375B4 Q27487013-9ED328F3-1BA2-4C88-A1AC-6981C2979451 Q27487992-909CA559-F913-4B20-99B5-6B77100E188A Q27489554-A7B27F28-2F9B-48D7-930B-4D73B077B0BB Q27489620-2073DA83-B256-4F5A-BEA3-610C93D2DDD6 Q28538841-5F59D6D8-8E7E-43A3-98E4-85A6891DC385 Q28578809-4049C043-0F31-41AE-98E4-A6C3F300C510 Q28740740-9E6AF09A-CD26-42D6-883E-4F4D1CB659BE Q33852635-49FB5158-2AC2-4AD9-8C10-A3D6D272B8A6 Q33909344-EEE9381F-8CD7-4FD0-9586-25CAB90C64E9 Q35097570-263EF2E7-2211-46BB-B3EE-A0A02040A6F5 Q35532741-DD2DAAB2-C343-4B7B-AD08-D3E562E373EC Q35702678-1AA51A16-D989-43D3-9210-FE18A04FD914 Q36093502-ED1619C3-7605-43F9-98B0-E1E407B33814 Q36136167-C7E0EFB1-CA27-4AF7-AAF4-006786CE75EB Q36179005-728CF161-0036-4FEE-A275-CDF0728EC080 Q37007003-F2F22FE8-28D7-47EC-A15A-E500BD039A95 Q37073267-2B35CAE0-8182-4248-97A3-E6B132352694 Q37120117-BACDDD0E-383B-4A76-A7B1-095606D8DD5A Q37324444-40D291B1-61BB-495A-93C8-170DE08A9162 Q37423499-989304F9-95CC-41B9-8618-D00C39EE729A Q37842337-62EDD75D-FE5B-4F9F-9201-BC33380D9C8B Q38963356-E8AC8BEF-F84C-427D-8AB2-F80B80E740C0 Q40073429-265B5EC0-35E6-4878-B505-FFB32B8074CE Q40149563-5D94184A-C030-49E7-BA94-4485F27C7141 Q40531040-4D8A74B6-6BDC-4AD0-BCDA-CC41F1E7A453 Q43040329-950D6417-B39E-45A4-8FCF-B2634B1C8FAA

P2860

West Nile virus/dengue type 4 virus chimeras that are reduced in neurovirulence and peripheral virulence without loss of immunogenicity or protective efficacy

http://www.wikidata.org/entity/Q27471660

description

2002 nî lūn-bûn

@nan

2002 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի մարտին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

West Nile virus/dengue type 4 ...... enicity or protective efficacy

@ast

West Nile virus/dengue type 4 ...... enicity or protective efficacy

@en

West Nile virus/dengue type 4 ...... enicity or protective efficacy

@nl

type

label

West Nile virus/dengue type 4 ...... enicity or protective efficacy

@ast

West Nile virus/dengue type 4 ...... enicity or protective efficacy

@en

West Nile virus/dengue type 4 ...... enicity or protective efficacy

@nl

prefLabel

West Nile virus/dengue type 4 ...... enicity or protective efficacy

@ast

West Nile virus/dengue type 4 ...... enicity or protective efficacy

@en

West Nile virus/dengue type 4 ...... enicity or protective efficacy

@nl

P1433

Q27471660-7E6419DD-7656-48CC-804E-FB4EEDC5871D

P1476

Q27471660-ACECE287-2DCC-4E3C-B021-82052FFEAEC4

P2093

Q27471660-0864E6B9-E2FD-4725-93B8-CE30AB92FF42

Q27471660-34505042-D6C3-4C6F-81F1-F9701F6AD947

Q27471660-9568C4D6-5C3E-4E0E-93E1-2B30515ECCA8

Q27471660-BAE601D4-1527-4690-955E-4226613AAA37

Q27471660-E9059D85-F173-4314-B929-7CDE52AD00DB

P2860

Q27471660-0FC5375F-7F25-491A-813D-60B83BE15376

Q27471660-110AA5D6-30AA-4FF2-AC5C-B5C6FD80F741

Q27471660-2A903AA9-2965-4DF6-9BCA-8258BA6D81BF

Q27471660-2F661B54-D859-42F3-928B-7B27C7E36DBE

Q27471660-36C58DDE-0E1F-45E0-BFF4-E9BDDFB66B0A

Q27471660-3E7FB9F6-78BE-44A3-BE2A-4EA9A17C93DA

Q27471660-438F0DB8-F6D4-4478-8716-6C7CC4AE408E

Q27471660-580CA6E3-419C-408F-BD62-CEE200D8D61F

Q27471660-7550EA56-4171-4ECF-9CBE-9E4BD373225C

Q27471660-874088EF-EB1F-4DBA-A949-9557943E7A90

P304

Q27471660-6918963C-F82F-4BA7-91A0-41D205A87AEC

P31

Q27471660-12613A52-7E96-4DD6-BC02-A8FB2AE3D3AB

P356

Q27471660-E03E1AD0-BE30-438E-A28F-FC3FFEFBEA4E

P407

Q27471660-89C654D7-CB4D-44C2-B8B9-E8D4A1637E22

P433

Q27471660-4EFD8CFF-0D79-4962-B2CB-A75CB7D73951

P478

Q27471660-35B41CD3-9331-4782-8636-7BF31392AB60

P577

Q27471660-152AAC98-7B1F-46B3-B5A4-46EDD81D7E1A

P5875

Q27471660-EBF1C628-3651-470F-BC85-0FE24CA7AF27

P698

Q27471660-8F365EEA-A60E-4D9A-AD1D-92D9901741CA

P921

Q27471660-13FE7544-95F5-4239-811D-9966FA0816B0

Q27471660-4AA3C75B-781E-4A16-AC6C-B11FC8EE2174

Q27471660-DB2F2F7E-F07F-48A5-9470-DAD585014940

P932

Q27471660-92C8E5F9-7917-41FE-9931-8493F24616C0

P356

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

West Nile virus/dengue type 4 ...... enicity or protective efficacy

@en

P2093

Alexander G Pletnev

http://www.w3.org/2001/XMLSchema#string

David W Vaughn

http://www.w3.org/2001/XMLSchema#string

Eric J Wagar

http://www.w3.org/2001/XMLSchema#string

Jim Speicher

http://www.w3.org/2001/XMLSchema#string

Robert Putnak

http://www.w3.org/2001/XMLSchema#string

P2860

Antigenic relationships between flaviviruses as determined by cross-neutralization tests with polyclonal antisera

Yellow fever/Japanese encephalitis chimeric viruses: construction and biological properties

Signal peptidase cleavage at the flavivirus C-prM junction: dependence on the viral NS2B-3 protease for efficient processing requires determinants in C, the signal peptide, and prM

Mutagenesis of the signal sequence of yellow fever virus prM protein: enhancement of signalase cleavage In vitro is lethal for virus production.

Chimeric dengue type 2 (vaccine strain PDK-53)/dengue type 1 virus as a potential candidate dengue type 1 virus vaccine

Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates

Chimeric yellow fever/dengue virus as a candidate dengue vaccine: quantitation of the dengue virus-specific CD8 T-cell response

Chemical mutagenesis of dengue virus type 4 yields mutant viruses which are temperature sensitive in vero cells or human liver cells and attenuated in mice.

Tick-Borne Langat/Mosquito-Borne Dengue Flavivirus Chimera, a Candidate Live Attenuated Vaccine for Protection against Disease Caused by Members of the Tick-Borne Encephalitis Virus Complex: Evaluation in Rhesus Monkeys and in Mosquitoes

Monkeys immunized with intertypic chimeric dengue viruses are protected against wild-type virus challenge

P304

3036-3041

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.022652799

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

99

http://www.w3.org/2001/XMLSchema#string

P577

2002-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11481666

http://www.w3.org/2001/XMLSchema#string

P698

11880643

http://www.w3.org/2001/XMLSchema#string

P921

West Nile virus

P932

122468

http://www.w3.org/2001/XMLSchema#string